This trial tests how the standard prostate cancer treatments, Leuprolide & Relugolix, affect quality of life, blood levels, cholesterol, & blood sugar.
- Prostate Cancer
1 Primary · 6 Secondary · Reporting Duration: At 9 months
Side Effects for
2 Treatment Groups
Arm B: Leuprolide
1 of 2
Arm A: Relugolix
1 of 2
110 Total Participants · 2 Treatment Groups
Primary Treatment: Arm A: Relugolix · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 18+ · Male Participants · 0 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Has the FDA sanctioned Relugolix for pharmaceutical use?
"With clinical data confirming a certain level of safety and the lack of evidence suggesting efficacy, Arm A: Relugolix received a score of 2." - Anonymous Online Contributor
Is there still availability for participation in this research endeavor?
"The information displayed on clinicaltrials.gov reveals that this medical study is not presently seeking applicants, however it was initially published on August 1st 2023 and last updated March 1st of the same year. Although no longer recruiting patients, there are 1318 other trials currently enrolling participants." - Anonymous Online Contributor